News Releases

Nov 12, 2015
OncoMed Pharmaceuticals to Present at Upcoming Investor Conferences

REDWOOD CITY, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and immuno-oncology pathways, today announced that Paul J. Hastings, Chairman and Chief Executive Officer, will speak at two upcoming investor conferences. 

  • Jefferies Autumn 2015 Global Healthcare Conference - November 18-19, 2015 - London
    OncoMed's corporate presentation is scheduled to take place at 2:00 pm GMT on November 19, 2015.
  • Piper Jaffray 27th Annual Healthcare Conference — December 1-2, 2015 - New York
    Paul Hastings will provide a fireside chat on Tuesday, December 1, 2015 at 8:30 a.m. ET

A live webcast of each presentation will be available through the OncoMed website in the Investor Relations section.  The webcast will also be archived and available for replay for up to 45 days.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics.  OncoMed has seven anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin-LGR.  OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK).  A wholly owned immuno-oncology candidate, GITRL-Fc, and an undisclosed target that is part of OncoMed's collaboration with Celgene are being advanced toward clinical trials in the 2016-2017 timeframe. 

Please see the company's website at for additional information.

Media & Investors
OncoMed Pharmaceuticals 
Michelle Corral
Senior Director, Investor Relations and Corporate Communications
(650) 995-8373

Shari Annes
Annes Associates
(650) 888-0902

OncoMed Pharmaceuticals, Inc. is a wholly-owned subsidiary of Mereo BioPharma Group plc.
Please visit our parent site for our Pipeline, Partnering Opportunities and Investors information.